- Home
- AEVA vs ZYME Comparison
AEVA vs ZYME Comparison
Compare AEVA & ZYME Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AEVA
- ZYME
- Stock Information
- Founded
- AEVA 2019
- ZYME 2003
- Country
- AEVA United States
- ZYME United States
- Employees
- AEVA N/A
- ZYME N/A
- Industry
- AEVA Auto Parts:O.E.M.
- ZYME Biotechnology: Pharmaceutical Preparations
- Sector
- AEVA Consumer Discretionary
- ZYME Health Care
- Exchange
- AEVA Nasdaq
- ZYME Nasdaq
- Market Cap
- AEVA 1.0B
- ZYME 867.6M
- IPO Year
- AEVA N/A
- ZYME 2017
- Fundamental
- Price
- AEVA $25.82
- ZYME $12.24
- Analyst Decision
- AEVA Buy
- ZYME Buy
- Analyst Count
- AEVA 6
- ZYME 7
- Target Price
- AEVA $16.20
- ZYME $19.50
- AVG Volume (30 Days)
- AEVA 2.0M
- ZYME 412.4K
- Earning Date
- AEVA 08-06-2025
- ZYME 07-31-2025
- Dividend Yield
- AEVA N/A
- ZYME N/A
- EPS Growth
- AEVA N/A
- ZYME N/A
- EPS
- AEVA N/A
- ZYME N/A
- Revenue
- AEVA $10,326,000.00
- ZYME $93,384,000.00
- Revenue This Year
- AEVA $94.59
- ZYME $44.71
- Revenue Next Year
- AEVA $165.22
- ZYME $34.57
- P/E Ratio
- AEVA N/A
- ZYME N/A
- Revenue Growth
- AEVA 95.90
- ZYME 85.05
- 52 Week Low
- AEVA $2.20
- ZYME $8.21
- 52 Week High
- AEVA $26.76
- ZYME $17.70
- Technical
- Relative Strength Index (RSI)
- AEVA 78.16
- ZYME 50.56
- Support Level
- AEVA $21.90
- ZYME $12.33
- Resistance Level
- AEVA $18.69
- ZYME $13.44
- Average True Range (ATR)
- AEVA 1.82
- ZYME 0.56
- MACD
- AEVA 0.33
- ZYME 0.05
- Stochastic Oscillator
- AEVA 90.96
- ZYME 50.52
About AEVA Aeva Technologies Inc.
Aeva Technologies Inc through its Frequency Modulated Continuous Wave (FMCW) sensing technology, designs a 4D LiDAR-on-chip that, along with its proprietary software applications, has the potential to enable the adoption of LiDAR across broad applications from automated driving to consumer electronics, consumer health, industrial automation, and security application. The company operates in North America, EMEA, and Asia. The company derives the majority of its revenue from North America.
About ZYME Zymeworks Inc.
Zymeworks Inc is a clinical-stage biopharmaceutical company dedicated to the discovery, development and commercialization of next-generation multifunctional biotherapeutics. Its suite of therapeutic platforms and its fully integrated drug development engine enables precise engineering of differentiated therapeutic product candidates. Its clinical candidate, zanidatamab, is a novel HER2-targeted bispecific antibody currently being evaluated in multiple Phase 1, Phase 2, and pivotal clinical trials globally as a targeted treatment option for patients with solid tumors that express HER2. The company is also advancing a deep preclinical pipeline in oncology and other therapeutic areas.